Trump administration announces funding for PTSD research on ibogaineWIRED investigation examines Jensen Huang's comments on defining women's power in techWalmart launches early Black Friday promotions on select giftsMint Mobile offers $500 discount on select new phones for new customers signing up for a yearRussia and Iran criticize U.S. Caspian task force amid reports of joint sanction evasion effortsNewly elected US lawmakers pose for traditional group photo at Capitol ahead of 120th Congress openingUS existing home sales drop to lowest monthly level in yearsPro-Palestine philanthropist faces US extradition hearing in SpainLewisham Islamic Centre criticizes charity watchdog over warning on Palestine commentsSenegalese wrestlers succeed in beach wrestling at Dakar Youth OlympicsUS nonprofits file lawsuit seeking pause on advanced AI model trainingDemocrats convene in Denver to discuss party direction after midterm victoriesUS releases report on $12bn from Venezuelan oil, mineral resourcesPope Leo XIV urges Catholic Church to address clergy sexual abuseShooting near White House results in death, suspect later found dead
All fact checks
AI analysis

Fact check

“The FDA will consider all information provided in response to this Request for Information (RFI) to inform whether and how these specific elements should be considered in its review of Investigational New Drug Applications (INDs) involving ibogaine.”
UnverifiableConfidence: LOW

Reasoning

The claim references an FDA statement about considering information from an RFI in IND reviews for ibogaine, but no documents or sources were provided to verify this policy or statement.

On confidence: No evidence was supplied to confirm or refute the claim.

Important context

The claim pertains to FDA regulatory procedures regarding ibogaine IND applications, which would require official FDA communications or policy documents for verification.

Evidence

No retrievable evidence was found; the verdict rests on the reporting itself and is marked accordingly.

Limitations

Evaluation is limited to the absence of supplied evidence; without access to FDA notices, guidance, or the specific RFI, the claim cannot be verified.

Last verified:
Oct 6, 2026, 4:16 AM CDT
Pipeline:
2.1.0
Claim type:
Factual

Where this claim appeared

Design and Safety Considerations for Clinical Trials Involving Ibogaine Drug Products; Request for Information

Federal Register · Drug Administration, Human Services Department, Food, Health